Zomig and Heart Problems

During previous clinical studies, heart problems -- including a heart attack, changes in heart rhythm, and cardiac arrest -- were reported as rare side effects of Zomig. However, this risk of heart problems appears to be higher in people with a history of heart problems and in those with risk factors for heart disease. Therefore, if you have a history of heart problems, you should not take this medicine. If you have risk factors for heart disease, be sure to talk with your healthcare provider about Zomig and heart problems.

 

An Overview of Zomig and Heart Problems

Zomig® (zolmitriptan) is a prescription drug used to treat migraine headaches. It is part of a class of migraine medications known as 5-HT agonists (or more commonly just "triptans").
 
Some people may experience side effects during treatment with Zomig, and heart problems are among these possible side effects. For this reason, people with a history of heart problems should not take Zomig. For those with risk factors for heart problems, Zomig should be used with caution.
 

Heart Problems With Zomig -- What's the Risk?

It is thought that heart problems with Zomig occur because Zomig can cause the blood vessels of the heart (known as coronary arteries) to spasm. This narrows the blood vessels and decreases the amount of oxygen- and nutrient-rich blood that is able to get to the heart muscle.
 
In previous clinical studies that looked at both the benefits and risks of Zomig, heart problems were seen in rare cases (less than 1 percent of people taking the medication). However, this risk was greater in those with a history of heart disease and in those with risk factors for heart disease. Heart problems were often quite serious and, in some cases, even resulted in loss of life. Some of these heart problems seen with Zomig include:
 
(Zomig and Heart Problems Continued: Page 2)
Add this article to your Favorites     Email this article     Print
Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;